Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The infused autograft lymphocyte-to-monocyte ratio (A-LMR) is a prognostic factor for survival in B-cell lymphomas post-autologous peripheral hematopoietic stem cell transplantation (APHSCT). Thus, we set out to investigate if the A-LMR is also a prognostic factor for survival post-APHSCT in T-cell lymphomas. Methods: From 1998 to 2014, 109 T-cell lymphoma patients that underwent APHSCT were studied. Receiver operating characteristic (ROC) and area under the curve (AUC) were used to identify the optimal cut-off value of A-LMR for survival analysis and k-fold cross-validation model to validate the A-LMR cut-off value. Univariate and multivariate Cox proportional hazard models were used to assess the prognostic discriminator power of A-LMR. Results: ROC and AUC identified an A-LMR ≥ 1 as the best cut-off value and was validated by k-fold cross-validation. Multivariate analysis showed A-LMR to be an independent prognostic factor for overall survival (OS) and progression-free survival (PFS). Patients with an A-LMR ≥ 1.0 experienced a superior OS and PFS versus patients with an A-LMR < 1.0 [median OS was not reached vs 17.9 months, 5-year OS rates of 87 % (95 % confidence interval (CI), 75-94 %) vs 26 % (95 % CI, 13-42 %), p < 0.0001; median PFS was not reached vs 11.9 months, 5-year PFS rates of 72 % (95 % CI, 58-83 %) vs 16 % (95 % CI, 6-32 %), p < 0.0001]. Conclusions: A-LMR is also a prognostic factor for clinical outcomes in patients with T-cell lymphomas undergoing APHSCT.

Original languageEnglish (US)
Article number5
JournalJournal of Hematology and Oncology
Volume8
Issue number1
DOIs
StatePublished - Jul 3 2015

Fingerprint

Peripheral Blood Stem Cell Transplantation
T-Cell Lymphoma
Hematopoietic Stem Cell Transplantation
Autografts
Monocytes
Lymphocytes
Survival
Disease-Free Survival
Confidence Intervals
ROC Curve
Area Under Curve
Survival Rate
B-Cell Lymphoma
Survival Analysis
Proportional Hazards Models
Multivariate Analysis

Keywords

  • Autograft absolute lymphocyte-to-monocyte count ratio
  • Autologous peripheral hematopoietic stem cell transplantation
  • Survival
  • T-cell lymphomas

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Molecular Biology

Cite this

@article{0d285daee318490cbfb8bcc4d5870af9,
title = "Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation",
abstract = "Background: The infused autograft lymphocyte-to-monocyte ratio (A-LMR) is a prognostic factor for survival in B-cell lymphomas post-autologous peripheral hematopoietic stem cell transplantation (APHSCT). Thus, we set out to investigate if the A-LMR is also a prognostic factor for survival post-APHSCT in T-cell lymphomas. Methods: From 1998 to 2014, 109 T-cell lymphoma patients that underwent APHSCT were studied. Receiver operating characteristic (ROC) and area under the curve (AUC) were used to identify the optimal cut-off value of A-LMR for survival analysis and k-fold cross-validation model to validate the A-LMR cut-off value. Univariate and multivariate Cox proportional hazard models were used to assess the prognostic discriminator power of A-LMR. Results: ROC and AUC identified an A-LMR ≥ 1 as the best cut-off value and was validated by k-fold cross-validation. Multivariate analysis showed A-LMR to be an independent prognostic factor for overall survival (OS) and progression-free survival (PFS). Patients with an A-LMR ≥ 1.0 experienced a superior OS and PFS versus patients with an A-LMR < 1.0 [median OS was not reached vs 17.9 months, 5-year OS rates of 87 {\%} (95 {\%} confidence interval (CI), 75-94 {\%}) vs 26 {\%} (95 {\%} CI, 13-42 {\%}), p < 0.0001; median PFS was not reached vs 11.9 months, 5-year PFS rates of 72 {\%} (95 {\%} CI, 58-83 {\%}) vs 16 {\%} (95 {\%} CI, 6-32 {\%}), p < 0.0001]. Conclusions: A-LMR is also a prognostic factor for clinical outcomes in patients with T-cell lymphomas undergoing APHSCT.",
keywords = "Autograft absolute lymphocyte-to-monocyte count ratio, Autologous peripheral hematopoietic stem cell transplantation, Survival, T-cell lymphomas",
author = "Porrata, {Luis F.} and Inwards, {David J.} and Ansell, {Stephen Maxted} and Ivana Micallef and Johnston, {Patrick Bruce} and William Hogan and Markovic, {Svetomir Nenad}",
year = "2015",
month = "7",
day = "3",
doi = "10.1186/s13045-015-0178-5",
language = "English (US)",
volume = "8",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation

AU - Porrata, Luis F.

AU - Inwards, David J.

AU - Ansell, Stephen Maxted

AU - Micallef, Ivana

AU - Johnston, Patrick Bruce

AU - Hogan, William

AU - Markovic, Svetomir Nenad

PY - 2015/7/3

Y1 - 2015/7/3

N2 - Background: The infused autograft lymphocyte-to-monocyte ratio (A-LMR) is a prognostic factor for survival in B-cell lymphomas post-autologous peripheral hematopoietic stem cell transplantation (APHSCT). Thus, we set out to investigate if the A-LMR is also a prognostic factor for survival post-APHSCT in T-cell lymphomas. Methods: From 1998 to 2014, 109 T-cell lymphoma patients that underwent APHSCT were studied. Receiver operating characteristic (ROC) and area under the curve (AUC) were used to identify the optimal cut-off value of A-LMR for survival analysis and k-fold cross-validation model to validate the A-LMR cut-off value. Univariate and multivariate Cox proportional hazard models were used to assess the prognostic discriminator power of A-LMR. Results: ROC and AUC identified an A-LMR ≥ 1 as the best cut-off value and was validated by k-fold cross-validation. Multivariate analysis showed A-LMR to be an independent prognostic factor for overall survival (OS) and progression-free survival (PFS). Patients with an A-LMR ≥ 1.0 experienced a superior OS and PFS versus patients with an A-LMR < 1.0 [median OS was not reached vs 17.9 months, 5-year OS rates of 87 % (95 % confidence interval (CI), 75-94 %) vs 26 % (95 % CI, 13-42 %), p < 0.0001; median PFS was not reached vs 11.9 months, 5-year PFS rates of 72 % (95 % CI, 58-83 %) vs 16 % (95 % CI, 6-32 %), p < 0.0001]. Conclusions: A-LMR is also a prognostic factor for clinical outcomes in patients with T-cell lymphomas undergoing APHSCT.

AB - Background: The infused autograft lymphocyte-to-monocyte ratio (A-LMR) is a prognostic factor for survival in B-cell lymphomas post-autologous peripheral hematopoietic stem cell transplantation (APHSCT). Thus, we set out to investigate if the A-LMR is also a prognostic factor for survival post-APHSCT in T-cell lymphomas. Methods: From 1998 to 2014, 109 T-cell lymphoma patients that underwent APHSCT were studied. Receiver operating characteristic (ROC) and area under the curve (AUC) were used to identify the optimal cut-off value of A-LMR for survival analysis and k-fold cross-validation model to validate the A-LMR cut-off value. Univariate and multivariate Cox proportional hazard models were used to assess the prognostic discriminator power of A-LMR. Results: ROC and AUC identified an A-LMR ≥ 1 as the best cut-off value and was validated by k-fold cross-validation. Multivariate analysis showed A-LMR to be an independent prognostic factor for overall survival (OS) and progression-free survival (PFS). Patients with an A-LMR ≥ 1.0 experienced a superior OS and PFS versus patients with an A-LMR < 1.0 [median OS was not reached vs 17.9 months, 5-year OS rates of 87 % (95 % confidence interval (CI), 75-94 %) vs 26 % (95 % CI, 13-42 %), p < 0.0001; median PFS was not reached vs 11.9 months, 5-year PFS rates of 72 % (95 % CI, 58-83 %) vs 16 % (95 % CI, 6-32 %), p < 0.0001]. Conclusions: A-LMR is also a prognostic factor for clinical outcomes in patients with T-cell lymphomas undergoing APHSCT.

KW - Autograft absolute lymphocyte-to-monocyte count ratio

KW - Autologous peripheral hematopoietic stem cell transplantation

KW - Survival

KW - T-cell lymphomas

UR - http://www.scopus.com/inward/record.url?scp=84938549626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938549626&partnerID=8YFLogxK

U2 - 10.1186/s13045-015-0178-5

DO - 10.1186/s13045-015-0178-5

M3 - Article

C2 - 26138828

AN - SCOPUS:84938549626

VL - 8

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

M1 - 5

ER -